Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?
Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.
He started the Dose of Digital blog in 2008, then left healthcare. Now, after more than two years away, Jonathan Richman says he's back in the business.
Haymarket Media launched the site PsychiatryAdvisor.com today.
The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.
Industry reined in commercial support for CME in 2013—the sixth consecutive annual decrease—data released today by the ACCME show.
In what amounts to a sudden about face, CMS wants to delete the Sunshine rule's exclusion for continuing medical education.
The solution: talk to patients.
The website is a joint effort between Merck and The Lancet.
An internal probe for a controversial ad for hypertension drug Blopress was released by Takeda, but the report is in Japanese.
A US Pharma juror's—and silver Lions Health winner's—opinion on why the Americans didn't fare well in Cannes, and tips for improvement
Farzad Mostashari is leading a startup to help primary care physicians create Accountable Care Organizations
The bedside decision-making app includes clinical trial and drug information as well as breaking news.
Will docs line up to glimpse their payment data—and get a chance to correct mistakes—or will low awareness overshadow the latest milestone in the law's roll-out?
The maker of an FDA-approved app says its algorithm can use images to assess surgery-related blood loss.
The pharma market research major is working on unifying into one company with two main product lines, and is also in the process of a re-brand.
Texting HCPs may be speedy, but a study finds some built-in risks.
The advertising watchdog gave drugmaker Alvogen 15 days to make amends.
With pollen season approaching its peak, drugmakers are educating doctors on a new class of allergy tablets. It could be a while before they're made available for patients.
Merck's lead digital health strategist and his business partner offer a glimpse of what's possible through pharma and EHR collaborations.
Eisai announced it was adding sales reps to promote its drug Belviq, while Vivus, maker of Qsymia, fights off a generic marketing application by Actavis.
A survey by investment firm Jefferies found that the temporary 2013 suspension had a minimal impact on how doctors perceive the drug.
A piece about obesity and Coca-Cola shows the widespread nature of conflict-of-interest discussions and concerns about the sway that honoraria and other goodies may exert on researchers.
A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.
A report of over 270,000 US medical sites signals that EHR adoption is no longer a luxury reserved for hospitals and health systems.
The FDA's proposed upgrade to its off-label distribution guidelines has some new features, but experts say it is unclear if this means more dollars will flow toward reprints.
They're not hiding their love or disdain for reform, including one who says the law brings bias into the exam room.
Researchers found that most healthcare apps have limited functionality, don't serve patients with multiple needs, and taper off when support is needed most. No wonder adoption is low.
EHRs could be a vehicle for pharma to find its way into the physician's workflow. First, industry needs to learn how to leverage them appropriately.
Growing client demand encouraged the agency to make its HCP content capabilities official.
How potential alignment between drug companies and physicians, via the EHR, could extend brand reach.
Doctors shared their information preferences with CMI/Compas, revealing ways marketers can better pace their communications to max out channels.
A survey by Athenahealth/ePocrates indicates that the digital habits of med students are in sync with those of their professional peers
Patient use of the professional app prompted the latest iteration, and the foundation behind it is set to launch a media push.
The duo whose nonprofit served as neutral ground for getting FDA and industry talking about digital marketing is starting a for-profit research and advisory firm.